Comparison · NCT03840148-9f2e44d0
Cefepime/VNRX-5133 (Taniborbactam) vs Meropenem: Clinical Success at Test of Cure (TOC) in the CE Population
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Cefepime/VNRX-5133 (Taniborbactam) vs Meropenem: Clinical Success at Test of Cure (TOC) in the CE Population. Trial comparisons, record NCT03840148-9f2e44d0. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03840148-9f2e44d0
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.875 | 0.839 | 0.904 | wilson | |
| Risk in group 2 | 0.827 | 0.767 | 0.873 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0485 | -0.0107 | 0.114 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.06 | 0.983 | 1.14 | log | |
| Odds ratio, group 1 over group 2 | 1.47 | 0.913 | 2.36 | log | |
| Number needed to treat, for one more participant with the outcome on Cefepime/VNRX-5133 (Taniborbactam) than on Meropenem | 20.6 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Cefepime/VNRX-5133 (Taniborbactam) | Cefepime/VNRX-5133 administered q8h intravenously (IV) over a 2-hour period.~Cefepime/VNRX-5133 (taniborbactam): Cefepime/VNRX-5133 administered q8h intravenously (IV) over a 2-hour period for 7 days (up to 14 days for patients with bacteremia). Patients will also receive meropenem placebo administered via IV over 30 minutes. | 343 | 392 | OG000 |
| Group 2 | Meropenem | Meropenem will be administered q8h IV over 30 minutes.~Meropenem: Meropenem will be administered q8h IV over 30 minutes for 7 days (up to 14 days for patients with bacteremia). Patients will also receive cefepime/VNRX-5133 placebo administered via IV over a 2-hour period. | 162 | 196 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Clinical Success at Test of Cure (TOC) in the CE Population
- Description
Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
- Time frame
- Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)
- Population
The CE analysis population consists of all patients in the ITT analysis population who had a diagnosis of cUTI; received treatment for ≥48 hours; were evaluated at EOT with a response that was not indeterminate; did not violate prior antibacterials exclusion or received concomitant antibiotic therapy with activity against baseline pathogens except for patients failing study drug; or had other confounding factors that interfered with the assessment of outcome including unblinding.
Source ClinicalTrials.gov
Trial
- Title
- Safety and Efficacy Study of Cefepime/VNRX-5133 in Patients With Complicated Urinary Tract Infections
- NCT number
- NCT03840148
- Phases
- PHASE3
- Conditions
- Urinary Tract Infections, Acute Pyelonephritis
- Interventions
- Cefepime/VNRX-5133 (taniborbactam), Meropenem
- Lead sponsor
- Venatorx Pharmaceuticals, Inc.
- Results first posted
- 2024-05-29
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03840148?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03840148-9f2e44d0